Applied Genetic Technologies (Applied Genetic Technologies) Inventory-to-Revenue : 0.00 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Applied Genetic Technologies's Average Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil. Applied Genetic Technologies's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

Applied Genetic Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2022 stayed the same from Jun. 2022 (0.00) to Jun. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Applied Genetic Technologies Inventory-to-Revenue Historical Data

The historical data trend for Applied Genetic Technologies's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Genetic Technologies Inventory-to-Revenue Chart

Applied Genetic Technologies Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Inventory-to-Revenue

Get a 7-Day Free Trial

Applied Genetic Technologies Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Applied Genetic Technologies's Inventory-to-Revenue

For the Biotechnology subindustry, Applied Genetic Technologies's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied Genetic Technologies's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Applied Genetic Technologies's Inventory-to-Revenue falls into.

Applied Genetic Technologies Inventory-to-Revenue Calculation

Applied Genetic Technologies's Inventory-to-Revenue for the fiscal year that ended in Jun. 2022 is calculated as

	Inventory-to-Revenue (A: Jun. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Jun. 2021 )	+	Total Inventories (A: Jun. 2022 ))	/	count )	/	Revenue (A: Jun. 2022 )
=	( (0	+	0)	/	1 )	/	0.325
=	0					/	0.325
=	0.00

Applied Genetic Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

	Inventory-to-Revenue (Q: Sep. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Sep. 2022 ))	/	count )	/	Revenue (Q: Sep. 2022 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

Applied Genetic Technologies (NAS:AGTC) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Applied Genetic Technologies's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2022 )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Applied Genetic Technologies's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2022 )	/	Average Total Inventories (Q: Sep. 2022 )
	=	0	/	0
	=

Applied Genetic Technologies Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Applied Genetic Technologies's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615

Website

https://www.agtc.com

Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.

Executives

Susan Schneider	officer: Chief Medical Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber	officer: Chief Financial Officer	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter	officer: See Remarks	7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds	officer: Chief Accounting Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer	director, officer: President and CEO	C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay	officer: General Counsel	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria	officer: Chief Scientific Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad	director	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik	10 percent owner	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v.	10 percent owner	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting	10 percent owner	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v.	10 percent owner	C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex	officer: General Counsel	C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615